Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are increasingly becoming popular in Sudan due to the rising incidence of bleeding disorders and surgical procedures.
Customer preferences: Patients with bleeding disorders, such as hemophilia, are the primary consumers of Anti-Fibrinolytic Drugs in Sudan. Additionally, these drugs are also used in surgical procedures to prevent excessive bleeding.
Trends in the market: The Anti-Fibrinolytic Drugs market in Sudan has been growing steadily due to the increasing number of surgical procedures and the rising incidence of bleeding disorders. The market is dominated by a few key players who offer a range of products to cater to the diverse needs of patients. The market is expected to continue to grow in the coming years due to the increasing awareness of bleeding disorders and the availability of advanced treatments.
Local special circumstances: The healthcare system in Sudan faces numerous challenges, including a shortage of skilled healthcare professionals, inadequate infrastructure, and limited access to essential medicines. These challenges have a significant impact on the availability and affordability of Anti-Fibrinolytic Drugs, particularly in rural areas. Despite these challenges, the government has taken several initiatives to improve the healthcare system, including increasing the budget for healthcare and investing in medical infrastructure.
Underlying macroeconomic factors: The Sudanese economy has been struggling due to political instability, economic sanctions, and the impact of the COVID-19 pandemic. These factors have led to a decline in the country's GDP and a rise in inflation. The healthcare sector has also been affected by these challenges, with limited investment in healthcare infrastructure and a shortage of essential medicines. However, the government has taken steps to address these challenges, including increasing the budget for healthcare and investing in medical infrastructure. These initiatives are expected to have a positive impact on the Anti-Fibrinolytic Drugs market in Sudan.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
